Patent intelligence · US
US 11427823
Targeted compositions
Targeted compositions
Patent details — US 11427823
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 30, 2022
- Expiration
- Aug 25, 2042
- Applicant
- ARBUTUS BIOPHARMA CORPORATION
- Claims
- 16
- CPC classes
- A61K, A61K47/549, A61K47/554, A61P
Quick answer
US 11427823 (Targeted compositions) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted Aug 30, 2022. Expires Aug 25, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ARBUTUS BIOPHARMA CORPORATION
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K47/549, A61K47/554, A61P, A61P1/16, A61P31/20
More from ARBUTUS BIOPHARMA CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 12357705
Negatively charged peg-lipid conjugates
granted -
US 12350383
Cationic lipids containing silicon
granted -
US 12251470
Lipid nanoparticle formulations
granted -
US 12129467
Non-liposomal systems for nucleic acid delivery
granted -
US 12083118
Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same
granted -
US 12043833
Targeted compositions
granted -
US 12042541
Lipids and compositions for the delivery of therapeutics
granted -
US 12023383
Lipid compositions
granted
Frequently asked questions
What is US patent 11427823?
US 11427823 (Targeted compositions) is held by ARBUTUS BIOPHARMA CORPORATION. Status: granted. Granted Aug 30, 2022. Expires Aug 25, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11427823?
ARBUTUS BIOPHARMA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 56 pharmaceutical patents for this assignee.
When does US 11427823 expire?
Our index shows an expiration date of Aug 25, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.